Background The monoclonal anti-CD20 antibody rituximab, combined with
chemotherapeutic agents, has been shown to prolong overall survival in physically fit …

Background Chronic lymphocytic leukaemia (CLL) accounts for 25% of all leukaemias and
is the most common lymphoid malignancy in western countries. Standard treatments include …

GAUGUIN evaluated the safety and efficacy of obinutuzumab (GA101) monotherapy in
patients with relapsed/refractory chronic lymphocytic leukemia (CLL). In phase 1 (dose …

In a phase II trial, we evaluated chlorambucil and rituximab (CLB‐R) as first‐line induction
treatment with or without R as maintenance for elderly chronic lymphocytic leukemia (CLL) …

Introduction: The last decade has witnesd immense progress in the treatment of chronic
lymphocytic leukemia (CLL). Chemoimmunotherapy (CIT) combining rituximab and …

Intensive chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab is the
standard first line treatment in younger and physically fit patients with chronic lymphocytic …

These NCCN Guidelines Insights summarize several key updates to the 2012 NCCN
Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Hodgkin's Lymphomas …

Hematologic malignancies are a common cause of morbidity and mortality among older
adults, who represent the majority of patients diagnosed with these diseases. Treatment …

Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in Western
countries with an incidence of 3.8 per 100,000 person-years [1]. CLL occurs twice as often in …

Die chronische lymphatische Leukämie (CLL) als häufigste Leukämie im Erwachsenenalter–
mit einer Inzidenz von bis zu 30 pro 100000 pro Jahr bei den über 70-Jährigen–ist in den …